First-line venetoclax-obinutuzumab +/− ibrutinib tops chemoimmunotherapy in advanced CLLMay 18, 2023B Cell Lymphoma
Benefits of Pola-R-CHP over other novel agents against newly diagnosed DLBCLApril 17, 2023B Cell Lymphoma
Addition of bortezomib to R-CHOP improves survival in DLBCL molecular subgroupsApril 17, 2023B Cell Lymphoma
Ibrutinib offers better efficacy and tolerability over idelalisib+rituximab in relapsed/refractory CLLApril 17, 2023B Cell Lymphoma
Dose-adjusted EPOCH and rituximab beneficial for selected older patients with high-risk DLBCLApril 17, 2023B Cell Lymphoma
Axi-cel a promising second-line treatment option for older patients with relapsed or refractory LBCLApril 17, 2023B Cell Lymphoma
Lenalidomide+rituximab+venetoclax a potential therapy option for untreated MCLApril 17, 2023B Cell Lymphoma
Higher rates of hospitalization, blood disorders, and infections among patients with MCLApril 17, 2023B Cell Lymphoma
